FSNUY
Fresenius SE & Co. KGaA
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Neutral
-20/100
Last price
12.37
▼ 0.06 (0.48%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
12.43
Day high
12.60
Day low
12.33
Volume
10.33K
Market cap
$27.87B
P/E (TTM)
15.27
52W range
10.33 – 33.93
Trailing performance
Returnvs SPY
1W
-1.98%
-3.9%
1M
-2.75%
-3.9%
3M
+1.39%
-3.1%
6M
-1.90%
-20.1%
YTD
-13.68%
-27.9%
1Y
-11.07%
-27.5%
3Y
+58.39%
-23.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on FSNUY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$27.87B
Enterprise value$38.71B
Revenue (TTM)$23.28B
Gross profit$5.90B
EBITDA$3.04B
Net income$1.56B
EPS (TTM)$0.81
Free cash flow$1.71B
Total cash$1.28B
Total debt$11.42B
Book value / share$9.84
Shares outstanding2.25B
Float1.64B
Short % of float—
Dividend yield2.46%
Beta (5Y)0.82
Valuation & profitability ratios
Trailing P/E15.27
Forward P/E4.29
PEG ratio0.78
Price / sales—
Price / book1.26
EV / revenue1.66
EV / EBITDA12.74
Gross margin25.35%
Operating margin10.63%
Profit margin6.54%
Return on equity8.29%
Return on assets3.43%
Debt / equity55.98
Current ratio1.28
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $22.87B | $21.95B | $21.07B | $21.53B | +4.2% |
| Operating revenue | $22.87B | $21.95B | $21.07B | $21.53B | +4.2% |
| Cost of revenue | $17.18B | $16.32B | $16.10B | $16.13B | +5.3% |
| Gross profit | $5.69B | $5.64B | $4.97B | $5.40B | +1.0% |
| Research & development | $633.00M | $641.00M | $661.00M | $639.00M | -1.2% |
| Selling, general & admin | $2.88B | $2.89B | $3.03B | $3.09B | -0.2% |
| Total operating expense | $3.51B | $3.56B | $3.79B | $3.59B | -1.5% |
| Operating income | $2.18B | $2.07B | $1.18B | $1.81B | +5.2% |
| Net interest income | -$320.00M | -$429.00M | -$398.00M | -$215.00M | +25.4% |
| Pre-tax income | $2.19B | $1.68B | $773.00M | $1.60B | +30.1% |
| Tax provision | $582.00M | $530.00M | $485.00M | $375.00M | +9.8% |
| Net income | $1.26B | $471.00M | -$594.00M | $1.37B | +168.4% |
| Net income to common | $1.26B | $471.00M | -$594.00M | $1.37B | +168.4% |
| Basic EPS | 0.56 | 0.21 | -0.26 | 0.61 | +166.7% |
| Diluted EPS | 0.56 | 0.21 | -0.26 | 0.61 | +166.7% |
| EBIT | $2.63B | $2.23B | $1.29B | $1.94B | +17.9% |
| EBITDA | $3.75B | $3.47B | $2.69B | $3.10B | +8.1% |
| Basic shares | 2.25B | 2.25B | 2.25B | 2.25B | 0.0% |
| Diluted shares | 2.25B | 2.25B | 2.25B | 2.25B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.31B | $2.05B | $2.29B | $2.57B | -36.1% |
| Cash & short-term investments | $1.31B | $2.05B | $2.29B | $2.57B | -36.1% |
| Accounts receivable | $3.56B | $3.50B | $3.67B | $7.16B | +1.7% |
| Inventory | $2.61B | $2.57B | $2.52B | $4.83B | +1.5% |
| Total current assets | $11.03B | $11.45B | $12.52B | $18.28B | -3.7% |
| Property, plant & equipment | $9.72B | $9.89B | $10.78B | $18.84B | -1.7% |
| Goodwill & intangibles | $16.72B | $17.51B | $17.62B | $35.83B | -4.5% |
| Total assets | $41.40B | $43.55B | $45.28B | $76.40B | -4.9% |
| Total current liabilities | $8.38B | $9.01B | $9.33B | $13.66B | -6.9% |
| Current debt | $1.30B | $2.60B | $2.38B | $2.19B | -49.9% |
| Long-term debt | $9.22B | $9.48B | $11.46B | $18.99B | -2.7% |
| Total debt | $11.93B | $13.58B | $15.83B | $27.76B | -12.1% |
| Total liabilities | $21.63B | $23.26B | $25.63B | $44.18B | -7.0% |
| Shareholder equity | $19.10B | $19.54B | $19.00B | $20.41B | -2.2% |
| Working capital | $2.64B | $2.44B | $3.19B | $4.62B | +8.5% |
| Net tangible assets | $2.39B | $2.04B | $1.38B | -$15.41B | +17.3% |
| Shares issued | 563.24M | 563.24M | 563.24M | 563.24M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.61B | $1.15B | $288.00M | $1.22B | — | +39.4% |
| Depreciation & amortisation | $1.12B | $1.24B | $1.40B | $1.16B | — | -9.6% |
| Change in working capital | $267.00M | $79.00M | $399.00M | -$257.00M | — | +238.0% |
| Operating cash flow | $2.57B | $2.45B | $4.46B | $4.20B | — | +5.2% |
| Capital expenditure | -$1.50B | -$1.06B | -$1.29B | -$1.19B | — | -41.2% |
| Investing cash flow | -$815.00M | -$510.00M | -$3.19B | -$2.61B | — | -59.8% |
| Share buybacks | — | — | — | — | $0 | — |
| Dividends paid | -$684.00M | — | -$551.00M | -$403.00M | -$1.07B | — |
| Financing cash flow | -$2.42B | -$2.18B | -$1.38B | -$1.60B | — | -11.0% |
| Free cash flow | $1.08B | $1.39B | $3.17B | $3.00B | — | -22.4% |
| End cash position | $1.58B | $2.28B | $2.56B | $2.75B | — | -30.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $5.95B | $5.82B | $6.16B | — | $5.65B | $5.71B | +2.2% |
| Operating revenue | $5.95B | $5.82B | $6.16B | — | $5.65B | $5.71B | +2.2% |
| Cost of revenue | $4.39B | $4.28B | $4.63B | — | $4.19B | $4.29B | +2.6% |
| Gross profit | $1.55B | $1.53B | $1.52B | — | $1.46B | $1.41B | +1.0% |
| Research & development | $167.00M | $163.00M | $170.00M | — | $164.00M | $140.00M | +2.5% |
| Selling, general & admin | $760.00M | $743.00M | $824.00M | — | $741.00M | $644.00M | +2.3% |
| Total operating expense | $918.00M | $933.00M | $1.06B | — | $899.00M | $725.00M | -1.6% |
| Operating income | $632.00M | $601.00M | $468.40M | — | $562.00M | $689.00M | +5.2% |
| Net interest income | -$80.00M | -$58.00M | -$66.00M | — | -$107.00M | -$93.00M | -37.9% |
| Pre-tax income | $535.00M | $577.00M | $607.00M | — | $493.00M | $614.00M | -7.3% |
| Tax provision | $136.00M | $132.00M | $180.00M | — | $147.00M | $141.00M | +3.0% |
| Net income | $382.00M | $435.00M | $361.00M | — | $330.00M | $229.00M | -12.2% |
| Net income to common | $382.00M | $435.00M | $361.00M | — | $330.00M | $229.00M | -12.2% |
| Basic EPS | 0.17 | 0.19 | — | — | 0.15 | 0.10 | -11.7% |
| Diluted EPS | 0.17 | 0.19 | — | — | 0.15 | 0.10 | -11.7% |
| EBIT | $632.00M | $601.00M | $920.00M | — | $562.00M | $689.00M | +5.2% |
| EBITDA | $902.00M | $874.00M | $1.23B | $740.00M | $830.00M | — | +3.2% |
| Basic shares | 2.25B | 2.25B | — | — | 2.28B | 2.25B | -0.3% |
| Diluted shares | 2.25B | 2.25B | — | — | 2.28B | 2.25B | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.28B | $2.06B | $1.31B | $1.23B | $2.39B | -37.9% |
| Cash & short-term investments | $1.41B | $3.95B | $1.31B | $1.39B | $2.53B | -64.2% |
| Accounts receivable | $4.36B | $3.96B | $3.56B | $3.80B | $3.75B | +10.1% |
| Inventory | $2.77B | $2.73B | $2.61B | $2.59B | $2.64B | +1.6% |
| Total current assets | $11.61B | $12.07B | $11.03B | $10.88B | $11.91B | -3.8% |
| Property, plant & equipment | $9.78B | $9.73B | $9.72B | $9.63B | $9.77B | +0.5% |
| Goodwill & intangibles | $16.75B | $16.76B | $16.72B | $16.83B | $17.25B | -0.1% |
| Total assets | $41.84B | $42.37B | $41.40B | $41.32B | $43.21B | -1.2% |
| Total current liabilities | $9.07B | $9.54B | $8.38B | $8.30B | $8.33B | -4.9% |
| Current debt | $1.69B | $2.19B | $1.30B | $2.09B | $2.06B | -22.9% |
| Long-term debt | $8.33B | $8.31B | $9.22B | $9.31B | $10.09B | +0.2% |
| Total debt | $11.42B | $11.90B | $11.93B | $12.85B | $13.63B | -4.1% |
| Total liabilities | $21.45B | $21.91B | $21.63B | $22.38B | $23.14B | -2.1% |
| Shareholder equity | $19.70B | $19.78B | $19.10B | $18.28B | $19.41B | -0.4% |
| Working capital | $2.54B | $2.53B | $2.64B | $2.58B | $3.58B | +0.5% |
| Net tangible assets | $2.95B | $3.02B | $2.39B | $1.45B | $2.16B | -2.3% |
| Shares issued | 563.24M | 563.24M | 563.24M | 563.24M | 563.24M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $398.00M | — | — | $360.00M | $346.00M | $473.00M | — |
| Depreciation & amortisation | $270.00M | $273.00M | $314.00M | $274.00M | $268.00M | — | -1.1% |
| Change in working capital | -$327.00M | -$298.00M | $778.00M | $171.00M | -$139.00M | — | -9.7% |
| Operating cash flow | $344.00M | $389.00M | $1.34B | — | $418.00M | $56.00M | -11.6% |
| Capital expenditure | -$241.00M | -$196.00M | -$725.00M | -$335.00M | -$234.00M | — | -23.0% |
| Investing cash flow | $41.00M | $29.00M | -$433.00M | — | -$167.00M | $59.00M | +41.4% |
| Dividends paid | — | — | $0 | — | -$560.00M | -$96.00M | — |
| Financing cash flow | -$1.17B | $45.00M | -$1.71B | — | -$1.40B | $26.00M | -2,708.9% |
| Free cash flow | $103.00M | $193.00M | $619.00M | $421.00M | $184.00M | — | -46.6% |
| End cash position | $1.28B | $2.06B | $1.58B | — | $1.23B | $2.39B | -37.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $5.79B | +5.6% |
| Next quarter | — | — | $6.34B | +6.3% |
| Current year | 1.14 | 1 | $23.76B | +3.9% |
| Next year | 2.89 | 2 | $24.98B | +5.1% |
Analyst targets & ownership
Mean target$16.11
High target$18.30
Low target$14.13
Implied upside30.23%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy1 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions0.00%
Institutions holding6
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
12.80
-3.34% from price
SMA 20
12.97
-4.65% from price
SMA 50
13.17
-6.09% from price
SMA 100
12.35
+0.17% from price
SMA 200
13.01
-4.89% from price
EMA 12
12.74
-2.92% from price
EMA 26
12.92
-4.26% from price
EMA 50
12.90
-4.12% from price
RSI (14)
32.2
Neutral
MACD (12,26,9)
-0.18
Hist -0.09
ATR (14)
0.46
3.75% of price
Realised vol 30D
21.1%
Annualised
Bollinger upper
13.64
20, 2σ
Bollinger lower
12.31
20, 2σ
50 / 200 cross
Golden
13.17 vs 13.01
Trend bias
Below 200
-4.89%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.58
Less volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
21.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-53.7%
Peak to trough
Max drawdown 5Y
-59.8%
Peak to trough
ATR 14
0.46
3.75% of price
Beta (reported)
0.82
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 3, 23 | Jefferies | UPGRADE | Hold | Buy |
Dividends & splits
Forward rate$0.30 / yr
Forward yield2.46%
5-year avg yield2.79%
Payout ratio37.73%
Ex-dividend dateMay 26, 2026
Next pay dateJun 10, 2026
Last split3:2
Split dateAug 5, 2014
Headlines
Vizient Expands Supply Assurance for IV Solutions Through Collaboration With Fresenius Kabi
Business Wire · 21h ago
Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion
PR Newswire · 6d ago
Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansion
PR Newswire · 6d ago
Fresenius Kabi Receives Pharmacy Strategic Programs Excellence Award From Vizient®
Business Wire · 7d ago
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Zacks · 7d ago
Waltz Health and Fresenius Kabi Expand Direct Access to Biosimilars Through Waltz Connect Platform
PR Newswire · 8d ago
mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide
PR Newswire · 19d ago
mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide
PR Newswire · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.